BTK and diffuse large B-cell lymphoma: CC-122 is currently in phase I trials in patients with newly diagnosed DLBCL or relapsed/refractory DLBCL, either as a single-agent (NCT01421524) [300–302, 303] (Additional file 1: Table S2) or in combination with the novel dual mTORC1/mTORC2 inhibitor CC-223 [304], the novel BTK inhibitor CC-293 [305] and/or rituximab (NCT02031419) as well as in combination with obinutuzumab, (NCT02417285) [303] (Additional file 1: Tables S5 and S14).